 AUSTIN, Texas, Sept. 7, 2021 PRNewswire -- Natera, Inc. NASDAQ: NTRA a leader in transforming care through genetic and cell-free DNA testing, today announced an agreement with NRG Oncology, a National Cancer Institute NCI-funded group, to use the Signatera personalized molecular residual disease MRD test in NRG-GI008: Colon Adjuvant Chemotherapy based on Evaluation of Residual Disease CIRCULATE-US, a prospective, multi-center, randomized clinical trial to investigate MRD-guided treatment strategies for patients with early stage colon cancer. 